PMID- 26604682
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20220316
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 9
DP  - 2015
TI  - Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and 
      leiomyosarcoma.
PG  - 5785-91
LID - 10.2147/DDDT.S92395 [doi]
AB  - OBJECTIVE: Trabectedin is effective in leiomyosarcoma and liposarcoma, especially 
      the myxoid variant, related to the presence of the FUS-CHOP transcript. We 
      evaluated the efficacy of trabectedin in specific subgroups of patients with soft 
      tissue sarcomas (STS). METHODS: Seventy-two patients with advanced 
      anthracycline-pretreated STS, who received trabectedin at a dose of 1.5 mg/m(2) 
      every 3 weeks by continuous 24-hour infusion, were retrospectively analyzed. Best 
      response rate according to Response Evaluation Criteria In Solid Tumors (RECIST) 
      criteria and severe adverse events (AEs) according to National Cancer Institute 
      Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.02) were evaluated. 
      Secondary endpoints included progression-free survival and overall survival (OS). 
      RESULTS: Median age was 48 (range, 20-75) years, with a median Eastern 
      Cooperative Oncology Group performance status of 0. The median number of previous 
      chemotherapy regimens was 1 (range, 0-5). Median number of trabectedin cycles was 
      3 (range, 1-17). About 69/72 patients (95.8%) were evaluable for response: 9 
      patients (13%) achieved partial response and 26 (37.7%) stable disease. According 
      to histotype, clinical benefit (partial response + stable disease) was reported 
      in synovial sarcoma (n=5), retroperitoneal liposarcoma (n=10), myxoid liposarcoma 
      (n=5), leiomyosarcoma (n=8), high-grade undifferentiated pleomorphic sarcoma 
      (n=5), Ewing/peripheral primitive neuroectodermal tumor (n=1), and malignant 
      peripheral nerve sheath tumor (n=1). Any grade AEs were noncumulative, 
      reversible, and manageable. G3/G4 AEs included anemia (n=1, 1.4%), neutropenia 
      (n=7, 9.6%), liver toxicity (n=6, 8.3%), and fatigue (n=2, 2.8%). With a median 
      follow-up time of 11 (range, 2-23) months, median progression-free survival and 
      OS of the entire cohort were 2.97 months and 16.5 months, respectively. 
      CONCLUSION: Our experience confirms trabectedin as an effective therapeutic 
      option for metastatic lipo- and leiomyosarcoma and suggests promise in synovial 
      sarcomas and high-grade undifferentiated pleomorphic sarcoma.
FAU - De Sanctis, Rita
AU  - De Sanctis R
AD  - Department of Medical Oncology and Haematology, Humanitas Cancer Center, IRCCS, 
      Rozzano, Italy.
FAU - Marrari, Andrea
AU  - Marrari A
AD  - Department of Medical Oncology and Haematology, Humanitas Cancer Center, IRCCS, 
      Rozzano, Italy.
FAU - Marchetti, Silvia
AU  - Marchetti S
AD  - Department of Medical Oncology and Haematology, Humanitas Cancer Center, IRCCS, 
      Rozzano, Italy.
FAU - Mussi, Chiara
AU  - Mussi C
AD  - Department of Surgical Oncology, Humanitas Cancer Center, IRCCS, Rozzano, Italy.
FAU - Balzarini, Luca
AU  - Balzarini L
AD  - Department of Radiology, Humanitas Cancer Center, IRCCS, Rozzano, Italy.
FAU - Lutman, Fabio Romano
AU  - Lutman FR
AD  - Department of Radiology, Humanitas Cancer Center, IRCCS, Rozzano, Italy.
FAU - Daolio, Primo
AU  - Daolio P
AD  - Department of Surgical Oncology, Orthopaedic Institute "G. Pini", Milan, Italy.
FAU - Bastoni, Stefano
AU  - Bastoni S
AD  - Department of Surgical Oncology, Orthopaedic Institute "G. Pini", Milan, Italy.
FAU - Bertuzzi, Alexia Francesca
AU  - Bertuzzi AF
AD  - Department of Medical Oncology and Haematology, Humanitas Cancer Center, IRCCS, 
      Rozzano, Italy ; Department of Medical Oncology, Adelaide and Meath Hospital, 
      Incorporating the National Children's Hospital (AMNCH), Dublin, Ireland.
FAU - Quagliuolo, Vittorio
AU  - Quagliuolo V
AD  - Department of Surgical Oncology, Humanitas Cancer Center, IRCCS, Rozzano, Italy.
FAU - Santoro, Armando
AU  - Santoro A
AD  - Department of Medical Oncology and Haematology, Humanitas Cancer Center, IRCCS, 
      Rozzano, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151027
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Dioxoles)
RN  - 0 (Tetrahydroisoquinolines)
RN  - ID0YZQ2TCP (Trabectedin)
SB  - IM
EIN - Drug Des Devel Ther. 2016;10:441. PMID: 26869765
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Alkylating/adverse effects/*therapeutic use
MH  - Dioxoles/adverse effects/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Leiomyosarcoma/drug therapy/pathology
MH  - Liposarcoma/drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Retrospective Studies
MH  - Sarcoma/*drug therapy/pathology
MH  - Survival Rate
MH  - Tetrahydroisoquinolines/adverse effects/*therapeutic use
MH  - Trabectedin
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4629957
OTO - NOTNLM
OT  - leiomyosarcoma
OT  - liposarcoma
OT  - soft tissue sarcoma
OT  - trabectedin
EDAT- 2015/11/26 06:00
MHDA- 2016/09/16 06:00
PMCR- 2015/10/27
CRDT- 2015/11/26 06:00
PHST- 2015/11/26 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
PHST- 2015/10/27 00:00 [pmc-release]
AID - dddt-9-5785 [pii]
AID - 10.2147/DDDT.S92395 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2015 Oct 27;9:5785-91. doi: 10.2147/DDDT.S92395. eCollection 
      2015.